Skip to main navigation

Codiak Biosciences

Investor Relations - Top Nav

Our Science
Our Science

Through our proprietary engEx™ Platform, we are harnessing the power of nature’s intercellular communication system to engineer a new class of medicines, exosome therapeutics.
Manufacturing
Pipeline & Programs
Pipeline & Programs

We are utilizing our engEx™ Platform to build a broad pipeline of therapeutic candidates that we believe can have a transformative impact on the treatment of a broad spectrum of diseases, with an initial focus on oncology and neurology.
About Us
About Us

At Codiak, we are working to create a major shift in the development of tomorrow’s medicines through scientific ambition, remarkable ingenuity and determined passion for improving patients’ lives.
Careers
Investors & Media
Investors & Media

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines.

News & Events

News & Events menu

Press Releases
Events
Presentations

lnk News

Press Releases

View All

November 23, 2020

Codiak BioSciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference

November 19, 2020

Codiak BioSciences Reports Third Quarter 2020 Financial Results and Operational Progress

November 9, 2020

Codiak Presents Preclinical Data at SITC 2020 Demonstrating Potential of engEx™ Engineered Exosomes to Stimulate Targeted, Integrated Anti-Tumor Immunity

lnk Past Events

Events

View Past Events

December 2, 2020 at 4:45 PM EST

Evercore ISI 3rd Annual HealthCONx Conference

Presentations

More information is coming soon.

Join our team of experts working at the forefront of advancing engineered exosomes. Explore Careers

© 2020 All Rights Reserved.

Footer Links

Contact
Privacy Policy
Terms of Use

LinkedIn Twitter